Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.

Dai W, Zeller C, Masrour N, Siddiqui N, Paul J, Brown R.

Clin Cancer Res. 2013 Oct 15;19(20):5788-97. doi: 10.1158/1078-0432.CCR-13-1217. Epub 2013 Aug 21.

2.

Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival.

Dai W, Teodoridis JM, Zeller C, Graham J, Hersey J, Flanagan JM, Stronach E, Millan DW, Siddiqui N, Paul J, Brown R.

Clin Cancer Res. 2011 Jun 15;17(12):4052-62. doi: 10.1158/1078-0432.CCR-10-3021. Epub 2011 Apr 1.

3.

Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.

Cohen S, Mosig R, Moshier E, Pereira E, Rahaman J, Prasad-Hayes M, Halpert R, Billaud JN, Dottino P, Martignetti JA.

Gynecol Oncol. 2014 Sep;134(3):591-8. doi: 10.1016/j.ygyno.2014.06.025. Epub 2014 Jul 1.

PMID:
24995581
4.

Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.

Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W.

J Natl Cancer Inst. 2015 May 20;107(7). pii: djv108. doi: 10.1093/jnci/djv108. Print 2015 Jul.

6.

Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinoma.

Romeo M, Karachaliou N, Chaid I, Queralt C, De Aguirre I, Del Carmen Gómez M, Sanchez-Ronco M, Radua J, Ramírez JL, Rosell R.

Int J Biol Markers. 2017 Mar 2;32(1):e90-e95. doi: 10.5301/jbm.5000223.

PMID:
27443420
7.

Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression.

Keita M, Wang ZQ, Pelletier JF, Bachvarova M, Plante M, Gregoire J, Renaud MC, Mes-Masson AM, Paquet ÉR, Bachvarov D.

Gynecol Oncol. 2013 Feb;128(2):356-63. doi: 10.1016/j.ygyno.2012.11.036. Epub 2012 Dec 2.

PMID:
23219462
8.

TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.

Brachova P, Mueting SR, Carlson MJ, Goodheart MJ, Button AM, Mott SL, Dai D, Thiel KW, Devor EJ, Leslie KK.

Int J Oncol. 2015 Feb;46(2):607-18. doi: 10.3892/ijo.2014.2747. Epub 2014 Nov 11.

9.

Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.

Unger U, Denkert C, Braicu I, Sehouli J, Dietel M, Loibl S, Darb-Esfahani S.

Virchows Arch. 2017 Feb;470(2):143-151. doi: 10.1007/s00428-016-2050-6. Epub 2016 Dec 2.

PMID:
27913862
10.

Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.

Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA, Wisman GB.

Gynecol Oncol. 2014 Jun;133(3):591-8. doi: 10.1016/j.ygyno.2014.03.557. Epub 2014 Mar 20.

PMID:
24657486
11.

Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.

Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W.

JAMA. 2011 Oct 12;306(14):1557-65. doi: 10.1001/jama.2011.1456. Erratum in: JAMA. 2012 Jan 25;307(4):363.

12.

The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.

Protopapas A, Diakomanolis E, Bamias A, Milingos S, Markaki S, Papadimitriou C, Dimopoulos AM, Michalas S.

Eur J Gynaecol Oncol. 2004;25(2):225-9.

PMID:
15032288
13.

Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.

Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, Le ND, Gilks CB, Singh N.

J Clin Oncol. 2015 Aug 1;33(22):2457-63. doi: 10.1200/JCO.2014.60.5212. Epub 2015 Jun 29.

PMID:
26124480
14.

Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.

Montavon C, Gloss BS, Warton K, Barton CA, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G, Hacker NF, Sutherland RL, Clark SJ, O'Brien PM.

Gynecol Oncol. 2012 Mar;124(3):582-8. doi: 10.1016/j.ygyno.2011.11.026. Epub 2011 Nov 22.

PMID:
22115852
15.

Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.

Fleming ND, Agadjanian H, Nassanian H, Miller CW, Orsulic S, Karlan BY, Walsh CS.

Cancer. 2012 Feb 1;118(3):689-97. doi: 10.1002/cncr.26329. Epub 2011 Jul 12. Erratum in: Cancer. 2012 Nov 1;118(21):5450.

16.

Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.

Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, Feilotter HE, Park PC, Squire JA.

BMC Cancer. 2013 Nov 16;13:549. doi: 10.1186/1471-2407-13-549.

17.

Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.

Liu Y, Yasukawa M, Chen K, Hu L, Broaddus RR, Ding L, Mardis ER, Spellman P, Levine DA, Mills GB, Shmulevich I, Sood AK, Zhang W.

JAMA Oncol. 2015 Jul;1(4):486-94. doi: 10.1001/jamaoncol.2015.1432.

18.

A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.

Kang J, D'Andrea AD, Kozono D.

J Natl Cancer Inst. 2012 May 2;104(9):670-81. doi: 10.1093/jnci/djs177. Epub 2012 Apr 13.

19.

Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.

Petrillo M, Zannoni GF, Beltrame L, Martinelli E, DiFeo A, Paracchini L, Craparotta I, Mannarino L, Vizzielli G, Scambia G, D'Incalci M, Romualdi C, Marchini S.

Ann Oncol. 2016 Apr;27(4):625-34. doi: 10.1093/annonc/mdw007. Epub 2016 Jan 17.

PMID:
26782955
20.

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.

Sayal K, Gounaris I, Basu B, Freeman S, Moyle P, Hosking K, Iddawela M, Jimenez-Linan M, Abraham J, Brenton J, Hatcher H, Earl H, Parkinson C.

Int J Gynecol Cancer. 2015 Jul;25(6):977-84. doi: 10.1097/IGC.0000000000000448.

Supplemental Content

Support Center